Sell Ranbaxy, says Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com told CNBC-TV18, "Ranbaxy Laboratories yesterday’s chart suggests that perhaps the smart money was pushing it only to get out. I would be a seller in Ranbaxy. A big down move yesterday can only be justified by another follow-through today. Therefore, a slightest weakness, sell it."

At 11:47 hrs Ranbaxy Laboratories was quoting at Rs 436, down Rs 8.15, or 1.83 percent. It has touched an intraday high of Rs 442.10 and an intraday low of Rs 433.30.
The company's trailing 12-month (TTM) EPS was at Rs 5.32 per share. (Mar, 2013). The stock's price-to-earnings (P/E) ratio was 81.87. The latest book value of the company is Rs 45.40 per share. At current value, the price-to-book value of the company was 9.59.